Is GLP3 the Same as Retatrutide? Naming vs Mechanism

There is no such thing as GLP-3. The proglucagon gene encodes glucagon, GLP-1, GLP-2, oxyntomodulin and glicentin, and the list ends there. No third glucagon-like peptide was ever discovered, and no GLP-3 receptor appears in any pharmacology reference.

Researchers ask us weekly whether GLP3 the same as retatrutide is a real chemical distinction or just a label, usually after seeing a vial marked 'GLP-3 RT' sitting beside one marked retatrutide. Our team has sourced and documented both. The naming is a marketing artifact, and it hides the one difference that actually matters for study design.

Is GLP3 the same as retatrutide?

Yes, in supplier shorthand. 'GLP3' and 'GLP-3 RT' are informal labels for retatrutide (LY3437943), an investigational triple receptor agonist active at the GIP, GLP-1 and glucagon receptors. GLP-3 is not a real hormone or receptor class. Confirm identity through the compound name, the developer code and the certificate of analysis, never the nickname.

The misconception worth correcting is the assumption that GLP3 the same as retatrutide implies GLP-3 is a newer, more powerful hormone class. The 3 counts receptors targeted, not hormones discovered. That same informal arithmetic turned tirzepatide into 'GLP-2' in forum slang, even though GLP-2 is a genuinely separate gut hormone with its own approved analog. What follows covers where the slang came from, how retatrutide differs mechanistically from survodutide and mazdutide, and what the published trial literature reports for each.

The hormone that does not exist, and the slang that built it

GLP-1 and GLP-2 are both real peptides cleaved from the same precursor protein, proglucagon, by prohormone convertase enzymes. In intestinal L cells, PC1/3 processing yields GLP-1, GLP-2, oxyntomodulin and glicentin. In pancreatic alpha cells, PC2 processing of the same precursor yields glucagon. GLP-2 has its own receptor and its own approved analog, teduglutide, used in short bowel syndrome. Nothing in that pathway produces a GLP-3.

So where did the term come from? Counting. Semaglutide hits one receptor and became the GLP-1 drug. Tirzepatide hits two, GIP and GLP-1, and picked up 'GLP-2' as nickname. Retatrutide hits three, GIP, GLP-1 and glucagon, and inherited 'GLP-3'. That is the entire etymology, which is why asking whether GLP3 the same as retatrutide gets a yes in practice and a flat no in pharmacology.

The confusion is not harmless. A literature search for GLP-3 returns nothing useful, because no journal indexes a hormone that was never characterised. A search for retatrutide or LY3437943 returns the peptide chemistry, the phase 1 pharmacokinetics and the phase 2 obesity results. We have watched capable researchers lose an afternoon chasing a name that does not exist in the indexed literature while the actual data sat one synonym away. Vendor slang is not a chemical identifier and never has been.

Is GLP3 the same as retatrutide when the vial says GLP-3 RT?

RT is simply an abbreviation of retatrutide, so GLP-3 RT and retatrutide describe the same investigational compound in nearly every catalog that uses the term. The developer code is LY3437943, assigned by Eli Lilly. Identity should never rest on a nickname though. In practice, the honest answer to is GLP3 the same as retatrutide lives on the certificate of analysis, not on the label.

A usable certificate shows four things: HPLC purity for that specific batch, mass spectrometry confirming the molecular weight matches the published sequence, peptide content determined by a real assay rather than gross vial weight, and a batch number that ties back to one synthesis run. A vial listing only 'GLP-3, 10mg' with no developer code, no sequence and no batch-linked analytics is telling you nothing verifiable. Every batch we release is documented, and our certificates of analysis are published rather than produced on request.

Handling follows the same rules as any lyophilised research peptide. Lyophilised material is generally stored at -20°C and protected from light. Once reconstituted with bacteriostatic water, laboratory documentation typically specifies 2°C to 8°C refrigeration and a limited working window. Temperature excursions denature peptide structure irreversibly, and no visual inspection catches it.

Retatrutide, survodutide and mazdutide are research-use-only compounds. They are not approved drugs and are not for human or veterinary consumption. Animal health questions belong with a licensed veterinarian, and metabolic health questions belong with a licensed physician.

What the glucagon arm adds that dual GIP and GLP-1 agonism cannot

Retatrutide's third target, the glucagon receptor, is the reason it is not simply a heavier version of tirzepatide. Glucagon receptor agonism acts largely on hepatocytes, where research describes increased hepatic fatty acid oxidation and raised energy expenditure. That is a catabolic lever, and it runs metabolically opposite to what most people assume an incretin-class peptide does.

The obvious problem with agonising the glucagon receptor is that glucagon raises blood glucose. The design logic of triple agonism is that the GLP-1 and GIP components supply insulinotropic, glucose-dependent counterbalance so the glucagon arm can contribute energy expenditure without unopposed hyperglycemia. Balance between the three activities, not the count of receptors, is the real engineering problem.

Here is the part most comparisons get wrong. Receptor count gets treated as a potency ranking, as though three beats two beats one. It does not work that way. The ratio of activity at each receptor determines both the effect and the ceiling, and in a triple agonist the tolerability signals reported in trials, including dose-dependent heart rate increases and gastrointestinal adverse events, are what constrain how far exposure can be pushed. A molecule with weaker glucagon activity may tolerate higher exposure than one with stronger glucagon activity, which is why raw receptor arithmetic predicts almost nothing.

The phase 2 obesity trial of retatrutide published in the New England Journal of Medicine in 2023 (PubMed 37366315) reported mean body weight reduction of 24.2% at 48 weeks in the highest dose arm. Its reported half-life supports once-weekly administration in trial protocols.

Survodutide vs retatrutide and mazdutide vs retatrutide

Survodutide and mazdutide are both dual GLP-1 and glucagon receptor agonists. Neither carries a GIP component, which is the cleanest way to frame survodutide vs retatrutide and mazdutide vs retatrutide: same glucagon lever, one fewer incretin arm.

Survodutide (developer code BI 456906) came out of a Boehringer Ingelheim and Zealand Pharma collaboration. Its phase 2 obesity results were published in the New England Journal of Medicine in 2024, and a separate phase 2 trial in metabolic dysfunction-associated steatohepatitis reported significantly higher rates of histological improvement versus placebo. The hepatic localisation of the glucagon receptor is precisely why this class keeps appearing in liver endpoints rather than weight endpoints alone.

Mazdutide (IBI362, also coded LY3305677) takes a different structural route. It is built on an oxyntomodulin analog scaffold, oxyntomodulin being the naturally occurring proglucagon product that already signals at both the GLP-1 and glucagon receptors. Innovent Biologics developed it under license from Eli Lilly and has advanced it through late-stage trials in China. So the survodutide peptide vs retatrutide comparison and the mazdutide comparison are not interchangeable. The two dual agonists differ from each other in backbone and in receptor activity ratio, not only from retatrutide.

In our experience supplying comparative in vivo programs, the researchers who get clean data are the ones who source the dual and triple agonists from one supplier under one analytical standard. Our survodutide and mazdutide listings carry batch-matched documentation for exactly that reason. Cross-supplier comparisons bury a purity variable nobody can correct for afterwards.

Mechanism and Published-Literature Comparison

This table maps each compound to its receptor targets, developer and stage, and what the peer-reviewed literature actually reports. It matters because the slang names collapse four genuinely different pharmacologies into one number.

What If: Naming and Sourcing Scenarios

What if a supplier lists GLP-3 and retatrutide as two separate products?

Treat that as a sourcing red flag and request the certificate of analysis for both listings before ordering either. If the analytics return the same molecular weight and the same sequence confirmation, they are one compound listed twice under different marketing names. If the documents differ or one listing has no batch-linked analytics at all, you are looking at an unverified product rather than a second molecule. No legitimate catalog needs two names for LY3437943.

What if the certificate names LY3437943 instead of retatrutide?

That is the correct, more precise identifier and should increase confidence rather than reduce it. LY3437943 is the developer code assigned during preclinical development, and it is the string that returns the pharmacokinetic and phase 1 literature most reliably. Certificates that cite only a nickname, with no code and no sequence, give you nothing to cross-check against published characterisation data.

What if a study design needs dual rather than triple receptor coverage?

Select a GLP-1 and glucagon dual agonist and state the receptor rationale in the protocol rather than defaulting to the newest molecule. Removing the GIP arm isolates glucagon-driven hepatic and energy expenditure effects, which is the reason survodutide and mazdutide keep appearing in liver-focused research. Adding a triple agonist arm afterwards without matched purity documentation introduces a confound that no statistical adjustment can remove.

The Blunt Truth About GLP-3 Branding

Let's be direct about this: 'GLP-3' exists because it sells, not because it describes anything. It is a nickname invented downstream of clinical development by people counting receptors, and it has no standing in biochemistry, in regulatory filings or in the indexed literature. Anyone asking whether GLP3 the same as retatrutide is really asking a sourcing question wearing a science costume. The answer is yes in catalogs, meaningless in pharmacology, and irrelevant next to the question that should have been asked first, which is what the certificate of analysis for that specific batch actually shows.

Comparative work across this class usually means running more than one molecule side by side. Our mazdutide and survodutide listings sit within the wider research catalog, every batch backed by published certificates of analysis, with fulfilment and facility details on our company information page.

Whether GLP3 the same as retatrutide counts as a meaningful distinction depends entirely on what you do with the answer. The nickname problem is a symptom of a larger habit in this market, which is buying a name instead of a molecule. Receptor count makes a tidy headline and a terrible specification. Sequence, purity, batch analytics and developer code are the only four things that survive contact with a peer reviewer, and none of them ever appear on a label that says GLP-3.

References

Peer-reviewed sources on Retatrutide indexed in PubMed, listed for research context. Real Peptides supplies Retatrutide for laboratory research use only.

1. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proceedings (Baylor University. Medical Center), 2025. PMID 40291085. doi:10.1080/08998280.2025.2456441
2. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Journal of basic and clinical physiology and pharmacology, 2025. PMID 40728138. doi:10.1515/jbcpp-2025-0113
3. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European journal of clinical pharmacology, 2024. PMID 38367045. doi:10.1007/s00228-024-03646-0
4. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism open, 2024. PMID 39318607. doi:10.1016/j.metop.2024.100321
5. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, obesity & metabolism, 2026. PMID 41090431. doi:10.1111/dom.70209
6. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026. PMID 42250575. doi:10.1016/S0140-6736(26)00967-0
7. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules, 2025. PMID 40563436. doi:10.3390/biom15060796
8. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025. PMID 40609566. doi:10.1016/S2213-8587(25)00092-0